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ABSTRACT 
 
Key findings of this national survey of non-cystic fibrosis bronchiectasis epidemiology were 
that its prevalence, incidence and mortality have all increased over recent years; we 
estimate that around 212,000 people are currently living with bronchiectasis in the UK, 
very much higher than commonly quoted figures. Bronchiectasis is more common in 
females than males; 60% of diagnoses are made in the over-70 age group. Regional 
differences in prevalence, incidence, mortality, and hospital admission were identified. 
An intriguing finding was that bronchiectasis is more commonly diagnosed in the least 
deprived sections of the population, in contrast to other respiratory disorders. 
 
INTRODUCTION 
 
As part of its 30th anniversary activities the British Lung Foundation commissioned a 
survey of the epidemiology of respiratory disease in the UK covering the period 2004-
2012/13 [1]. Findings pertaining to non-cystic fibrosis bronchiectasis are presented here. 
 
METHODS 
  
Prevalence and incidence rates were estimated from The Health Improvement Network 
(THIN) records for 2004-13; this general practice database represents ~ 5 per cent of the 
population and is based on physician diagnoses as recorded in electronic primary care 
medical records. The data were scaled up using population estimates to produce 
estimated total figures for the UK population. Whole population numbers were produced 
by calculating the sum of the expected numbers in each region, broken down by age and 
sex, estimated by multiplying the relevant rate by the Office for National Statistics 
population estimates for each subgroup in each year; region-specific estimates are 
standardised against the full registered THIN population in each year. 95% Confidence 
Intervals (CIs) for unstandardized rates were estimated as for simple proportions; CIs for 
standardised estimates were obtained using the Tiwari modified gamma method [2]. The 
Townsend deprivation index (assigned at full postcode level) was used to estimate the 
impact of social deprivation on prevalence and incidence. Mortality data were obtained 
from the Office for National Statistics for England and Wales, the General Register Office 
for Scotland and the Northern Ireland Statistics and Research Agency. Age-standardised 
mortality ratios by region were calculated separately for males and females over the five-
year period 2008-2013. The WHO Europe Hospital Morbidity Database was used to analyse 
total hospital admissions. Regional variations in hospital admissions were produced by 
looking at age-standardised emergency hospital admissions ratios; the sources for these 
were the relevant government agencies for England, Scotland, Wales and Northern 
Ireland. Our findings were compared with previously published data. 
 
RESULTS 
  
For full tabulated data see the Supplementary File (online only). An estimated 211,598 
(C.I. 207,135 – 216,019) people in the UK were living with bronchiectasis in 2012. From 
2008 to 2012 prevalence increased by 20%, with the number of people estimated to be 
living with bronchiectasis going up by ~40,000. In 2012, 379 (370 - 387) females and 
281(273 – 289) males per 100,000 had bronchiectasis. 
 
More women than men had the condition throughout the years 2004–12; around 35% more 
women than men are diagnosed with bronchiectasis each year. Approximately 60% of 
bronchiectasis diagnoses are made in people aged over 70. 
 
A higher proportion of people have bronchiectasis in the West Midlands than elsewhere in 
the UK, and a lower proportion in the South East of England. This was seen throughout the 
years 2004–12.  
 
Intriguingly, and in contrast to other lung diseases, figures for 2004–12 show that the 
chances of being diagnosed with bronchiectasis are lowest in the most deprived sections of 
the population and increase with reducing deprivation.  
 
In recent years, there has been an increase in the rate of first diagnoses of bronchiectasis 
in primary care. 33 (31 – 35) people per 100,000 were newly diagnosed in 2012, up from 20 
(19 – 22) per 100,000 in 2004. 
 
In 2012, 1,567 people in the UK were recorded as dying from bronchiectasis (0.3 per cent 
of all deaths and 1.4 per cent of deaths from lung disease), up from 1,150 in 2008. 123 
were aged 15–64 and 1,444 were aged 65 and above; no deaths from bronchiectasis were 
recorded in the age range >28 days – 14yrs. In 2012, of the 1,567 people who died from 
bronchiectasis, 661 were males and 906 were females. There were higher mortality rates 
in the North East, the North West, the East Midlands, the West Midlands and the South 
East of England than in the UK generally. There were notably lower death rates in the East 
of England, London and the South West than in the UK generally. The death rate in 
Scotland was slightly lower, and in Northern Ireland slightly higher, than for the UK as a 
whole. 
 
During the period 2008-12 there were 32,365 admissions to UK hospitals for bronchiectasis 
(12,539 males and 19,826 females).There were higher rates of emergency admission in 
Northern Ireland, and in the North East, North West, Yorkshire and the Humber, and East 
Midlands regions of England than in the UK as a whole. Admission rates were notably lower 
in the South East and South West of England, and in Scotland and Wales, compared with 
the UK generally. 
 
DISCUSSION 
  
Our estimate of 211,598 people in the UK living with bronchiectasis is very considerably 
higher than official estimates; the UK National Health Service states that ‘around 5 in 
every 1,000 adults in the UK have the condition’ [3]. Given a UK adult population of 
approximately 52million [4], this would give a prevalence of ~50,000. The difference is not 
accounted for by inclusion of children in our figures, as there were only an estimated 4638 
subjects <18yr. Other research published recently broadly agrees with our findings, and 
suggests that bronchiectasis prevalence in the UK could even be in excess of 300,000 [5]. 
More research is required to confirm the number of people living with the condition, and 
to determine whether bronchiectasis is becoming more common, or being diagnosed more 
accurately (or both); as a general comment, the quality of diagnosis and the extent of 
misdiagnosis in surveys like this are unknown.  
 
Truly assessing incidence and prevalence at a population level is complex given the 
current disease definition requires both clinical symptoms and imaging (high resolution 
computerised tomography) changes [6]. However, globally there has been a shift, with 
bronchiectasis in children under 5 and those over 75 at increased risk of disease in 
particular [7]. In addition, there appears to be a steady increasing prevalence [8-10]. A 
recent worldwide review suggested that increasing incidence and prevalence might be 
largely associated with a globally ageing population [11].  
 
The reasons for prevalence of the condition being more frequent in less-deprived subjects 
could include better access to diagnostic services in this group, more deprived people 
being labelled as having COPD rather than bronchiectasis, and higher mortality among the 
most deprived. However, most information on bronchiectasis comes from registry studies, 
from which the patient population may be more severe or not as generalisable as those 
captured from using routine data. This may also be the reason for the inverse association 
seen with socioeconomic status and bronchiectasis incidence.    
Our finding that mortality from the disease is increasing is in line with the findings of 
Roberts and Hubbard of a 3% annual increase in mortality between 2001-7 [12]. Prognosis 
is disease severity and co‐morbidity dependent and in a tertiary referral centre in the UK, 
male gender, age, respiratory function and Pseudomonas aeruginosa were all found to be 
independently associated with mortality [13].  
 
 
CONCLUSIONS 
Bronchiectasis represents a considerably larger than appreciated, and increasing burden on 
UK health services [14]. 
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